Search Results
Aug 12, 2026, 13:34 ET Shatterproof Walk to End Addiction Returns to Dallas as Community Rallies Around Recovery and Hope
as part of Shatterproof's national effort to transform how addiction is prevented, treated, and understood in America.Although Dallas County drug overdose deaths decreased by 15% in 2024, 529 people still lost their lives to overdose. Non-fatal opioid-related EMS responses increased by 4%, with
More news about: Shatterproof
Aug 12, 2026, 13:33 ET Shatterproof Walk to End Addiction Returns to D.C. as Community Rallies Around Recovery and Hope
transform how addiction is prevented, treated, and understood in America.Although drug overdose deaths in Washington, D.C. decreased by 31% in 2024, 446 people still lost their lives to overdose. Non-fatal drug overdose hospitalizations also declined, but 538 Washington, D.C. residents were hospitalized
More news about: Shatterproof
Aug 12, 2026, 13:33 ET Shatterproof Walk to End Addiction Returns to Los Angeles as Community Rallies Around Recovery and Hope
America.Although Los Angeles County drug overdose deaths decreased by 21% in 2024, 1,791 people still lost their lives to overdose. Non-fatal drug overdose hospitalizations also declined by 9%, but 3,819 Los Angeles County residents were hospitalized in 2024. Most drug overdose deaths and non-fatal hospitalizations
More news about: Shatterproof
Aug 12, 2026, 13:15 ET CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).The HOPE-3 Trial Breakthrough and Subsequent Capital RaiseOn
More news about: Hagens Berman Sobol Shapiro LLP
Aug 12, 2026, 13:12 ET American Ventures CEO Shravan Parsi Joins Bisnow Panel on Austin's Mixed-Use Future
americanventures.com.About Shravan ParsiShravan Parsi is the CEO and Founder of American Ventures. A former pharmaceutical scientist who developed patented drug products before turning to real estate, he bought his first Texas investment property in 2003 and has since invested in roughly 4,400 multifamily units
More news about: American Ventures
Aug 12, 2026, 10:31 ET CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
development programs across the FDA's biologics and drug review centers.In April 2026, Autolus Therapeutics unveils new ROKA Real-World and pediatric data supporting obe-cel in ALL.In January 2026, the FDA awarded Orphan Drug Designation (ODD) to CTD402, an innovative allogeneic
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 10:07 ET WSE UPCOMING DEADLINE: Levi & Korsinsky Alerts Wise Group plc Stockholders of Securities Class Action - Contact the Firm
monitoring systems described as reviewing hundreds of data points in real time were inadequate to detect laundering, fraud, corruption and drug trafficking links.The lawsuit contends disclosure of a pending national trust bank application was positioned so as to minimize the risk that
More news about: Levi & Korsinsky, LLP
Aug 12, 2026, 10:01 ET Cancer Tumor Profiling Market worth $19.87 billion by 2031 - Exclusive Report by MarketsandMarkets™
and stronger pharmaceutical–diagnostic collaborations are also supporting the adoption of tumor profiling across routine care, clinical trials, and drug development.Assays, kits, reagents, and consumables accounted for the largest share of the global cancer tumor profiling market, by offering,
More news about: MarketsandMarkets
Aug 12, 2026, 10:00 ET PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
applications.Eratrectinib marks Nanjing's first innovative drug approval this year. Through innovative cyclic structural optimization, it delivers more potent and highly selective inhibition of TRK kinases, overcoming structural limitations and drug‑resistance drawbacks of first‑generation agents at the
More news about: Jiangsu Vcare Pharmatech Co., Ltd.
Aug 12, 2026, 10:00 ET Integrity Partners with Fast-Growing Meraz Health Insurance Agency to Bring AI-Enhanced Client Support to More Americans
AgencyMeraz Health Insurance Agency is a Temecula, California-based insurance brokerage specializing in Medicare Advantage, prescription drug and Medicare supplement plans. The firm has a successful, decade-long track record and deep commitment to the Latino community. It has also developed
More news about: Integrity
Aug 12, 2026, 09:01 ET Propel Bio Partners Highlights Progress of EIT Pharma Under Leadership of CEO Dr. Leen Kawas
hepatitis D (CHD), and Lambda, its Phase 2 investigational treatment for severe acute viral respiratory infections. FDA recently accepted Lonafarnib's New Drug Application which follows Lonafarnib completing its D-LIVR study, the largest clinical trial conducted to date in chronic hepatitis D, which enrolled
More news about: Propel Bio Partners
Aug 12, 2026, 09:00 ET New study from CVS Caremark and Employee Benefit News shows how employers rely on their pharmacy benefit manager to create sustainable pharmacy solutions
working with drug manufacturers to negotiate affordable drug prices for
More news about: CVS Health
Aug 12, 2026, 09:00 ET OneDigital Deepens Impact Studio with AI-Powered Intelligence as Cost Containment Remains Employers' Top Priority
confidence to turn insight into action.""For a level-funded client with historically low utilization, Impact Studio flagged a spike in prescription drug costs mid-year, before it showed up in the renewal," commented Melinda Kubovcik Quiroga, Benefits Consultant at OneDigital. "We were able to target
More news about: OneDigital
Aug 12, 2026, 08:35 ET EQ Bank announces the biggest-ever giveaway of 25 million PC Optimum™ points and hosts interactive pop-ups in Loblaws, turning Canadians' everyday moments into everyday wins
PC Optimum™ members are automatically entered when they make a purchase of $20 or more at a participating Loblaw-affiliated grocery store or Shoppers Drug Mart and scan their PC Optimum™ card via their PC Optimum™ App or their digital wallet at checkout. For full contest details, including email submission,
More news about: EQ Bank
Aug 12, 2026, 08:30 ET Improve Drug Solubility from Formulation to Scale-Up, Upcoming Webinar Presented by Quotient Sciences and NGT Biopharma Consultants, Hosted by Xtalks
TORONTO, Aug. 12, 2026 /PRNewswire/ -- Poor drug solubility continues to be one of the most significant challenges in small molecule drug development, impacting bioavailability, formulation design, clinical performance, timelines and overall
More news about: Xtalks
Aug 12, 2026, 08:30 ET Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
clinical trial success through personalized integrative treatment.Supported by emerging FDA frameworks for drug-software combination products and regulatory alignment, the Hybrid Drug model is rapidly gaining industry momentum. The Company recently announced a strategic collaboration with Merck
More news about: Remepy
Aug 12, 2026, 08:30 ET Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard for the industry. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached preclinical
More news about: Insilico Medicine
Aug 12, 2026, 08:30 ET IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash positionCAESAREA,
More news about: IceCure Medical
Aug 12, 2026, 08:30 ET Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
INGREZZA® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA
More news about: Neurocrine Biosciences, Inc.
Aug 12, 2026, 08:17 ET Ivonescimab Plus Chemotherapy Approved for First-Line Squamous NSCLC; HARMONi-6 Establishes New Gold Standard in Lung Cancer Treatment
(9926.HK) ("Akeso" or the "Company") today announced that the China National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for ivonescimab injection in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung
More news about: Akeso, Inc.
Aug 12, 2026, 08:15 ET Employers with Claims Data Access Take More Action on Healthcare Costs, National Alliance of Healthcare Purchaser Coalitions Survey Finds
and usable data.Key FindingsAffordability pressures remain concentrated in drug prices, high-cost claims and hospital prices. Employers cite drug prices (77%), high-cost claims (75%) and hospital prices (68%) as the top significant threats.Employers
More news about: National Alliance of Healthcare Purchaser Coalitions
Aug 12, 2026, 08:09 ET Iterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith
metastatic colorectal cancer (mCRC) and other Wnt-driven cancers."Manuel and Bob bring exceptional expertise in clinical development, oncology drug advancement, company building, and strategic partnering at a pivotal moment for Iterion," said Rahul Aras, PhD, President and Chief Executive Officer
More news about: Iterion Therapeutics
Aug 12, 2026, 08:01 ET Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
stated: "Achieving these additional new patents extend our patent estate protection as we further develop ibezapolstat and our innovative, AI-supported drug discovery platform."Robert J. DeLuccia, Executive Chairman of Acurx, stated, "We believe Acurx's ibezapolstat and preclinical pipeline of systemically
More news about: Acurx Pharmaceuticals, Inc.
Aug 12, 2026, 08:00 ET Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would
More news about: Citius Oncology, Inc.
Aug 12, 2026, 08:00 ET Dove Deodorant Celebrates the Style, Confidence and Culture of the 2026 US Open as Official Sponsor of Underarms
Essentials, Caring Coconut, and more. Suggested retail price: $8.99 (Dry Spray) / $7.99 (Stick). Dove Antiperspirant is now available at major mass, food, drug, and club retailers nationwide.About DoveDove started its life in 1957 in the US, with the launch of its iconic Beauty Bar and
More news about: Dove